Market Intel: Martin Leon's TAVR Technology Tour Of The Future
Transcatheter aortic valve replacement pioneer Martin Leon discussed what is coming down the pike for technologies in the TAVR and heart valve device space at the recent Transcatheter Cardiovascular Therapeutics (TCT) conference in San Diego. Here is a run-down of what he highlighted, including AI-driven technologies that promise to improve patient access and outcomes. This is the first of a two-part series focusing on innovations in interventional cardiology.
You may also be interested in...
EU Investment Looks To Regenerate Tissue, As Well As Its Economy
Xeltis, a Netherlands-based company producing cardiovascular implants to stimulate natural regeneration of biological tissue, has received funding from the European Union’s rescue fund.
Start-Up Spotlight: Innovative Cardiovascular Solutions Hopes To Win Regulatory Nod For Embolic Protector For TAVR
Transcatheter aortic valve replacement (TAVR) is performed routinely using devices providing protection from stroke as standard of care. However, cerebral embolic protection devices currently available do not capture and remove emboli from all three vessels leading to the brain. The Emblok Embolic Protection System from Innovative Cardiovascular Solutions (ICS) has developed an embolic filter designed to protect all three cerebral vessels during TAVR and remove debris from the entire circulatory system.
2018 Earnings Spotlight: Transcatheter Valve Repair Remains Big Drivers For Medtronic, Edwards, Abbott
Reported sales and earnings from the publicly traded cardiovascular device companies in 2018 were generally strong, led by transcatheter aortic valve replacement devices, but some sectors of the industry, especially ventricular assist devices and peripheral drug-coated balloons, face significant challenges. Here's a recap of results from the cardio device companies that have reported so far, with a focus on Medtronic, Edwards, and Abbott.